TABLE 2.

Drug interactions between tuberculosis (TB) and potential COVID-19 medications

WHO: World Health Organization; INH: isoniazid; RIF: rifampicin; EMB: ethambutol; PZA: pyrazinamide; LFX: levofloxacin; MFX: moxifloxacin; BDQ: bedaquiline; LZD: linezolid; CFZ: clofazimine; Cs: cycloserine; DLM: delamanid; IMI/CIS: imipenem/cilastin; MEM: meropenem; AMI: amikacin; STR: streptomycin; ETO: ethionamide; PTO: prothionamide; PAS: p-aminosalicylic acid; CYP: cytochrome P450; UGT: UDP glucuronosyltransferase. ^#: recommended based on predicted interaction; ^¶: UGT 1A1 is involved in moxifloxacin metabolism and could be involved in umifenovir metabolism (mainly UGT 1A9); ⁺: both drugs are metabolised by CYP3A4; ^§: CYP3A4 is involved in the metabolism of baloxavir (minor extent) and umifenovir, and clofazimine is a CYP3A4 inhibitor; ^ƒ: both drugs primarily undergo renal excretion.